The amyloid precursor protein controls PIKfyve function by Balklava, Zita et al.
RESEARCH ARTICLE
The Amyloid Precursor Protein Controls
PIKfyve Function
Zita Balklava1, Christian Niehage2, Heather Currinn1, Laura Mellor3, Benjamin Guscott1,
Gino Poulin3, Bernard Hoflack2, ThomasWassmer1*
1 Aston University, School of Life and Health Sciences, Aston Triangle, Birmingham, B4 7ET, United
Kingdom, 2 Biotechnologisches Zentrum, TU-Dresden, Tatzberg 47–49, 01307 Dresden, Germany,
3 University of Manchester, Michael Smith Building, Oxford Road, Manchester, M13 9PT, United Kingdom
* t.wassmer@aston.ac.uk
Abstract
While the Amyloid Precursor Protein (APP) plays a central role in Alzheimer’s disease,
its cellular function still remains largely unclear. It was our goal to establish APP function
which will provide insights into APP's implication in Alzheimer's disease. Using our recently
developed proteo-liposome assay we established the interactome of APP's intracellular
domain (known as AICD), thereby identifying novel APP interactors that provide mechanis-
tic insights into APP function. By combining biochemical, cell biological and genetic
approaches we validated the functional significance of one of these novel interactors.
Here we show that APP binds the PIKfyve complex, an essential kinase for the synthesis of
the endosomal phosphoinositide phosphatidylinositol-3,5-bisphosphate. This signalling
lipid plays a crucial role in endosomal homeostasis and receptor sorting. Loss of PIKfyve
function by mutation causes profound neurodegeneration in mammals. Using C. elegans
genetics we demonstrate that APP functionally cooperates with PIKfyve in vivo. This regula-
tion is required for maintaining endosomal and neuronal function. Our findings establish an
unexpected role for APP in the regulation of endosomal phosphoinositide metabolism with
dramatic consequences for endosomal biology and important implications for our under-
standing of Alzheimer's disease.
Introduction
The transmembrane protein Amyloid Precursor Protein (APP, NCBI: NM_000484) is the cen-
tral player in Alzheimer’s disease, as patients with mutations in the APP gene develop a familial
form of Alzheimer’s disease [1, 2]. APP is processed by beta and gamma secretases into three
main fragments: the beta amyloid peptide (approximately 40 amino acids in length) which is
released from neurons, the extracellular domain of APP (sAPPb) and the intracellular domain
termed AICD. Cleavage of APP by the gamma secretase complex is instrumental in Alzhei-
mer’s disease as documented by the identification of familial Alzheimer’s disease mutations in
gamma secretase complex subunits (reviewed in [3]).
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Despite the importance of APP in Alzheimer's disease it still remains unclear what exactly
the physiological function of this molecule is. Due to its prototypical structure APP was sug-
gested to engage in cell signalling through proteolytic cleavage by beta and gamma secretases
in a fashion highly similar to that of the Notch signalling receptor [4]. Indeed, analogous to
Notch signalling, gamma secretase mediated release of AICD from the membrane has been
suggested to mediate signalling to the nucleus (reviewed in [5]).
Arguing for a role of APP in cell signalling but proposing an entirely different mechanism
the Drosophila homologue of APP, APPL, was shown to be involved in Wnt/planar cell polarity
signalling via the Abelson kinase [6]. Furthermore, APPL was shown to regulate axonal out-
growth and neuronal regeneration after brain injury [7]. Numerous additional roles have been
ascribed to APP (reviewed in [8]), among them an involvement in synapse organisation [9].
Despite these observations no coherent model of APP function has emerged.
APP, as a type-I transmembrane protein, is known to cycle between the plasma membrane,
endosomes and the trans-Golgi network [10]. It was shown to be sorted from the limiting
membrane of sorting endosomes for recycling to the trans-Golgi network requiring a traffick-
ing complex known as the Retromer [11]. How the trafficking of APP and, more specifically,
its endosomal sorting is linked to its proposed function in cell signalling remains unclear.
Endosomal sorting requires the endosomal phospholipid phosphatidylinositol-3-phosphate
(PI(3)P). This phosphoinositide provides membrane attachment for numerous endosomal
sorting complexes, Retromer sorting nexins being a well characterised group [12–14]. Addi-
tionally, the PI(3)P derived phosphatidylinositol-3,5-bisphosphate (PI(3,5)P2) is required for
Retromer dependent transport [15]. This lipid is produced by the PI(3)P-specific PIKfyve
kinase (also known as Fab1) that produces PI(3,5)P2. How exactly PI(3,5)P2 controls endo-
some-to-TGN transport is not currently clear. In addition to regulating endosome-to-TGN
transport, PI(3,5)P2 controls endosomal morphology and function [16, 17]. PI(3,5)P2, regulates
calcium permeability of endosomes via the TRP channel TRPML1 [18]. This is essential for
endosomal homeostasis and the degradative capability of the endosomal system. Defects in
TRPML1 lead to mucolipidosis type IV, a form of lysosomal storage disease that causes pro-
found neurodegeneration [19]. The most visible consequence of loss of the PI(3,5)P2-produc-
ing enzyme PIKfyve, induced either by RNAi suppression [15], expression of a kinase-dead
mutant [20], mutation [21] or pharmacological inhibition [22] is the extreme swelling of late
endosomes to form vacuoles.
PIKfyve functions as part of a conserved protein complex together with its co-activators
Vac14 and Fig 4, (also known as ArPIKfyve and Sac3, respectively) [23, 24]. Crucially, mouse
Fig 4 loss-of-function mutations or Vac14 knock-out mutants not only reduce PI(3,5)P2 levels
but also lead to profound neurodegeneration, resulting in perinatal death of the animals [21,
25]. Furthermore, mutations identified in the human Fig 4 gene lead to neurodegeneration in
humans including Charcot-Marie-Tooth syndrome and Amyotrophic Lateral Sclerosis [21,
26].
In this study we demonstrate that the key player in Alzheimer's disease, APP, interacts with the
PIKfyve complex and regulates the PIKfyve pathway in C. elegans, establishing an entirely novel
role for APP. The unexpected link between APP and endosomal phosphoinositide metabolism
may suggest a novel and surprising mechanism for neurodegeneration in Alzheimer's disease.
Results
APP binds Vac14 of the mammalian PIKfyve complex
For understanding the elusive physiological role of APP we studied the interactome of APP's
intracellular domain (termed AICD) using an in-vitro reconstitution system that we have
APP Controls PIKfyve Function
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recently established [27]. In this system AICD was coupled to the surface of liposomes to
mimic the organisation of its intracellular domain in the native APP together with a membrane
context [28]. These so-called 'proteo-liposomes' were then used to recruit interaction partners
followed by isolation and identification by mass spectrometry [27–29].
Combining AICD proteo-liposomes with label-free mass spectrometry [30] we established
the interactome of APP's intracellular domain and, surprisingly, found all three subunits
of the mammalian PIKfyve complex, namely PIKfyve (NCBI: NM_015040), Vac14 (NCBI:
NM_018052) and Fig 4 (NCBI: NM_014845) to associate with APP's intracellular domain
(Fig 1). Given that inactivation of the PIKfyve complex leads to neurodegeneration and that
APP plays a key role in Alzheimer's disease this finding prompted us to investigate this interac-
tion in more detail.
We confirmed the interaction between the intracellular domain of APP and Vac14 and the
PIKfyve complex by analysing the protein recruitments using Western blotting, showing that
Vac14 of the PIKfyve complex binds specifically to AICD-presenting proteo-liposomes while
no significant amounts of Vac14 were found in any of three different, negative controls (Fig 1).
APP co-localises and co-migrates with Vac14 in mammalian cells
When analysing the steady state localisation of APP and Vac14 in HeLa cells by co-expressing
APP-CFP and Vac14-mCIT we found them to display strong colocalisation on vesicles (Addi-
tional line scans are presented in S1 Fig). Some of these were positive for EEA1 indicating early
endosomes while some were LampI positive late endosomes (Fig 1). The dynamic association
of APP with Vac14 was also observed in live-cell imaging where APP co-localises and co-
migrates with Vac14 on tubules and vesicles moving through the cytoplasm (Fig 1). Addition-
ally, we detected significant colocalisation on mobile vesicles when expressing only the intracel-
lular domain of APP, AICD, fused to mCherry together with Vac14 (Fig 1). This is interesting
given that AICD, lacking a transmembrane domain, is expected to be cytosolic. However, these
data show that a portion of AICD is clearly membrane associated and colocalises with Vac14.
These data are consistent with the APP/Vac14 interaction established in Fig 1 and suggest that
APP associates with the PIKfyve complex in cells via its intracellular domain.
Analysis of APP and PIKfyve function in C. elegans
What is the function of the protein-protein interaction between APP and the PIKfyve complex
in-vivo? Currently it is not clear how PIKfyve function is regulated in multicellular organisms.
The fact that APP binds the PIKfyve activator Vac14 raised the possibility that APP may con-
trol PIKfyve activity. For testing this hypothesis we used the genetic model organism Caenor-
habditis elegans. The significant advantage of C. elegans is that only one orthologue of APP
exists (named apl-1, NCBI: NM_076469). In contrast, in mammals the APP-like gene family
consists of APP, APLP-1 and APLP-2. Mouse genetics clearly demonstrated a high level of
functional redundancy between these three genes, considerably complicating the analysis of
APP gene function in mammals [31].
Both APL-1 and PIKfyve (PPK-3 in C. elegans, NCBI: NM_077754) are essential for worm
development and viability [32, 33]. The most prominent phenotype of apl-1 null alleles is
developmental arrest during larval stages caused by a loose cuticle. This lethal phenotype is res-
cued by the expression of the soluble, extracellular domain of APL-1 [32]. Whether APL-1 has
additional functions that are masked by the severity of the cuticle phenotype remains unclear.
The PIKfyve orthologue PPK-3 is also essential and required for embryogenesis [33]. Addi-
tionally, PPK-3 plays an important role in endosomal homeostasis. Partial loss-of-function
alleles (hypomorphs) lead to a drop in PI(3,5)P2 levels and cause the formation of large
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Fig 1. Vac14 associates with the intracellular domain of APP (AICD) biochemically and in HeLa cells. (A) Proteo-liposome recruitment analysed by
mass spectrometry allowed the identification of the intracellular interactome of APP. A Vulcan plot showing that PIKfyve, Vac14 and Fig 4 of the mammalian
PIKfyve complex were significantly enriched in AICD proteo-liposomes (right quadrant) compared to controls (left). The dashed line indicates the 0.05
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vacuoles in hypodermal and intestinal cells, mirroring closely the defects induced by loss of
mammalian PIKfyve [33]. The vacl-14 gene (NCBI: NM_059814), the C. elegans orthologue of
mammalian Vac14, has not been characterised in C. elegans to date.
First, we wanted to test whether in C. elegans the putative Vac14 orthologue VACL-14 plays
a similar role as Vac14 in the mammalian complex and is indeed required for the activation of
PPK-3. We tested this by creating the ppk-3(n2835); vacl-14(ok1877) double mutant which
showed synthetic lethality, confirming that in C. elegans VACL-14 is necessary for full PPK-3
function and suggesting that the C. elegans complex functions similarly as the human complex.
Truncation of APL-1 leads to vacuole formation
To test whether APL-1 and the PPK-3 complex share a common function we analysed the phe-
notypes of apl-1, ppk-3 and vacl-14mutant alleles. For APL-1 we chose to study the yn5 dele-
tion in which the 3'-end of the gene encoding the transmembrane domain and intracellular
domain are deleted [32]. The yn5 allele thus represents a powerful tool for characterising the
role of the cytoplasmic domain of APL-1 without additional, deleterious effects caused by lack
of the extracellular domain [32]. This approach allowed us to characterise phenotypes that are
masked by the lethality of apl-1 null mutants. According to our working hypothesis APL-1
binds the PPK-3 complex via its intracellular domain and controls its activity. Loss of the intra-
cellular domain of APL-1 will prevent it from binding to the PPK-3 complex and disrupt PPK-
3 regulation. By consequence, APL-1 mutants should have a similar phenotype as PPK-3 loss-
of-function mutations.
Reduced PPK-3 activity by partial loss of function mutations in ppk-3 or deletion of its acti-
vator VACL-14 led to the formation of large vacuoles that are most easily visible in hypodermal
cells ([33] and Fig 2). Interestingly, when analysing the apl-1(yn5)mutant we observed hypo-
dermal vacuolation similar to that of ppk-3 and vacl-14mutants. This showed that the apl-1
(yn5)mutant phenocopies the partial loss of PPK-3 function (Fig 2 and [32]).
APL-1 functionally cooperates with PPK-3
While this observation suggests that APL-1 and PPK-3 may share a common function it is not
clear whether they act in the same pathway. To test this we analysed the epistasis of the apl-1
and ppk-3 genes. For this we combined the apl-1(yn5)mutation with hypomorphic alleles of
ppk-3. For reducing PPK-3 activity two hypomorphic ppk-3 alleles were used. ppk-3(n2668),
introducing a point mutation in the catalytic loop, significantly reduced PPK-3 activity [33]. A
weaker allele, ppk-3(n2835), leads to the formation of a truncated PPK-3 lacking the C-terminal
eleven amino acids [33]. Additionally, we utilised the vacl-14(ok1877) deletion mutant. Using
these mutants we created double mutants in the apl-1, ppk-3 and vacl-14 genes and compared
their phenotypes. In all three double mutants [apl-1(yn5); vacl-14(ok1877), apl-1(yn5) ppk-3
(n2835) and apl-1(yn5) ppk-3(n2668)] the accumulation of strongly swollen vacuoles was
significance threshold. (B) Western blotting confirmed the enrichment of Vac14 by AICD presenting proteo-liposomes while the intracellular domain of the
none-related receptor Sortilin and two additional controls (a non-related control peptide designated as 'control 1' or coupled cysteine 'control 2'–both
described in [27]) failed to bind Vac14, showing that Vac14 specifically associates with the intracellular domain of APP. (C) APP expressed as a C-terminal
CFP fusion displayed strong colocalisation with Vac14-mCit in HeLa cells. Limited colocalisation of APP and Vac14 could be observed on early endosomes
(labelled with EEA1) and late endosomes/lysosomes labelled with LampI, as indicated by arrows on the insets. Bar, 20 μm. (D) Line scans (indicated by the
red line in (C) demonstrated strong colocalisation between APP and Vac14. (E) In live-cell imaging APP fused to mCherry displayed co-movement with
Vac14-mCit positive vesicles and tubular carriers (arrows) that track through the cytoplasm. (F, G) (S1 Video). AICD fused to mCherry also colocalised with
Vac14-mCit in live cell imaging (arrows) (S2 Video). (G) Four individual vesicles positive for both AICD and Vac14 were tracked and the first image of the
sequence overlayed with the traces to illustrate comigration of AICD and Vac14. Note that in live cell imaging due to the delay caused by the change of filters
on fast moving vesicles the staining in the red and green channels are slightly displaced. Bar, 5μm.
doi:10.1371/journal.pone.0130485.g001
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evident (Fig 2 and S2 Fig). These proved to be significantly more numerous compared to single
mutants or control animals (Fig 2), showing that truncation of APL-1 considerably enhanced
the defects caused by reduced PPK-3 activity. This was particularly evident in the apl-1
(yn5) ppk-3(n2668) double mutant containing the stronger ppk-3mutant allele. These animals
were filled with vacuoles along the entire length of the animal in both the hypoderm and intes-
tine (Fig 2A and S2 Fig). The strength of the phenotypic effect of this double mutant precluded
us from counting individual vacuoles, as large portions of the animals were filled with vacuoles.
Moreover, these animals were unable to produce any viable offspring and the strain was non-
viable. Thus the truncation mutation in apl-1(yn5) combined with the ppk-3(n2668) point
mutation are synthetically lethal, demonstrating that APL-1 is required for PPK-3 function for
suppressing vacuoles and maintaining viability.
Fig 2. APL-1 interacts genetically with the PIKfyve complex genes vacl-14 and ppk-3. (A) Mutations in apl-1, ppk-3 and vacl-14 led to the formation of
vacuoles in the C. elegans intestine and hypoderm (indicated by arrows) apparent in the anterior tips of the worms as observed by Differential Interference
Contrast (DIC) microscopy. Combination of apl-1, ppk-3 and vacl-14 mutations in double mutant worms strongly enhanced this phenotype (* indicate very
large vacuoles), particularly evident in the apl-1(yn5) ppk-3(n2668) double mutant. (B) Box plots demonstrated that the number of vacuoles in apl-1/ppk-3
and apl-1/vacl-14 double mutants is significantly increased compared to the single mutants (Wilcoxon rank test, p<0.01, n20 per strain), demonstrating that
APL-1 functionally interacts with the PPK-3 complex. This showed that the C-terminal domain of APL-1 is necessary for suppressing vacuole formation
induced by loss of PPK-3 and VACL-14 activity. Bar, 50 μm.
doi:10.1371/journal.pone.0130485.g002
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For independent confirmation of the results obtained using the apl-1(yn5)mutant we used
RNAi suppression of APL-1 and showed that knock-down of APL-1 led to the accumulation of
huge vacuoles in the hypoderm and intestine of ppk-3mutant animals compared to wildtype
controls (S3 Fig), mirroring the effect of truncating APL-1. These data show that it is indeed
the loss of APL-1 that enhances loss of PPK-3 function.
If loss of APL-1 exacerbates the effects of PPK-3 impairment it is reasonable to assume that
overexpression of APL-1 may rescue the PPK-3 deficiency phenotype. We tested this by
expressing APL-1::GFP (characterised in [32]) in both hypomorphic ppk-3mutant strains and
measured the number of vacuoles. In Fig 3 it is shown that overexpression of APL-1::GFP sig-
nificantly reduced the number of vacuoles in both ppk-3mutants. These data are compatible
with APL-1 functioning within the PPK-3 pathway.
While APL-1 and PPK-3 appear to act in the same pathway it was not clear whether APL-1
acts upstream or downstream of PPK-3. Furthermore we have not fully excluded the possibility
that APL-1 and PPK-3 share a common function but act in parallel pathways.
Fig 3. Overexpression of APL-1 reduces vacuolar pathology caused by hypomorphic PIKfyve complexmutants. (A, B) Overexpression of APL-1::
GFP (established in [32]) significantly reduced the number of vacuoles in PPK-3 partial loss-of-function mutant animals (Wilcoxon rank test, p<0.01, n25
per strain). Note that in the case of the stronger hypomorphic ppk-3(n2668) mutant APL-1::GFP expression, while strongly ameliorating the phenotype, failed
to fully rescue the vacuolar phenotype.
doi:10.1371/journal.pone.0130485.g003
APP Controls PIKfyve Function
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Overexpression of APL-1 ameliorated the partial loss of PPK-3 function induced by hypo-
morphic ppk-3 alleles. If APL-1 acted downstream of PPK-3, overexpression of APL-1 should
also ameliorate the phenotype caused by complete loss of PPK-3 function in a ppk-3 null
mutant. Similarly, if APL-1 functions in a pathway parallel to PIKfyve, overexpression of APL-
1 should also rescue the phenotype of a ppk-3 null allele. In contrast, overexpression of APL-1
should not result in a rescue if APL-1 functions upstream of PPK-3. We tested the hypothesis
that APL-1 functions upstream of PPK-3 by overexpressing APL-1::GFP in the homozygous
ppk-3(mc46) null mutant [33]. ppk-3 null animals from heterozygous hermaphrodite mothers
grow up to the adult stage but fail to produce any viable offspring. Overexpression of APL-1::
GFP in hermaphrodites did not rescue lethality of their offspring. Additionally, we studied vac-
uolation in the anterior tip of young apl-1::GFP; ppk-3(mc46) adults by measuring the area of
the anterior tip covered by vacuoles. This was necessary as the vacuolation phenotype in these
animals was so pronounced that it was rarely possible to discriminate individual vacuoles
because of their fused appearance (Fig 4). An average 17% of the anterior tip was covered by
vacuoles in both the ppk-3(mc46) and the apl-1::GFP; ppk-3(mc46) animals, showing that APL-
1 overexpression did not rescue the ppk-3 null phenotype.
Taken together, APL-1::GFP expression is able to rescue the vacuolation phenotype of hypo-
morphic ppk-3 alleles while it appears to be unable to rescue a ppk-3 null allele, suggesting that
APL-1 acts upstream of PPK-3. One caveat of this analysis is that vacuolation may not be a
very sensitive measure of PPK-3 function which may not allow to detect subtle changes of
PPK-3 activity. Thus we cannot fully rule out the possibility that APL-1 may act in a pathway
parallel to PPK-3.
However, given that APP interacts with the PIKfyve complex in mammals (Fig 1) the most
plausible explanation is that of APP/APL-1 binding to and activating PIKfyve/PPK-3.
APP controls endo- and lysosomal homeostasis together with PIKfyve
The PIKfyve complex is known to regulate several trafficking steps during the maturation of
endosomes [15, 24, 34]. As the vacuoles induced by loss of PPK-3 function were shown to be of
endosomal/lysosomal origin [15, 18] our data suggest that APL-1 participates in the regulation
of endosomal homeostasis through activation of the PPK-3 complex. We therefore character-
ised the endosomal and lysosomal markers RAB-5, RAB-7 and LMP-1. The early endosomal
marker RAB-5 appeared to be largely unaffected by single and double mutations in apl-1, ppk-
3 or vacl-14 (S4 Fig) in agreement with previous data, demonstrating that PIKfyve affects
mainly late endosomal compartments [15, 25]. In contrast, the late endosomal and lysosomal
markers RAB-7 and LMP-1 were profoundly altered in the apl-1(yn5) ppk-3(n2835) and the
apl-1(yn); vacl-14(ok1877) double mutants and showed late endosomes to be clustered together
(Fig 5). These data were corroborated by RNAi suppression of APL-1 in vacl-14 and ppk-3
mutants expressing GFP::RAB-7 in which loss of APL-1 by RNAi suppression enhanced late
endosomal pathology caused by loss of PPK-3 function (S5 Fig). These defects were observed
both in the hypoderm as well as in the intestine. When studying the expression of a promoter
fusion of APL-1 with GFPWiese et al. could not to detect APL-1 expression in the intestine
using a 5'-UTR fusion presumed to contain the complete APL-1 promoter [35]. We reassessed
the expression pattern of APL-1 using a fosmid from the TransgeneOme project in which a
genomic copy of APL-1 was tagged with GFP [36]. We created a transgenic line (OL0186) by
microinjection of the APL-1 fosmid followed by analysis of APL-1::GFP expression. Overall
the expression pattern was similar to those previously described [32, 35] with APL-1 expression
detectable in head muscle cells, head neurons as well as the nerve chords. However, an impor-
tant difference was that APL-1::GFP expression was also detected in the intestine (S6 Fig).
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These data indicate that the previously utilised 5'-UTR fusions of APL-1 drive APL-1 expres-
sion in most, but not all the tissues compared to a genomic construct. These data suggest that
APL-1 is expressed in the C. elegans intestine in addition to the previously established tissues.
This is fully compatible with the intestinal phenotype observed in the double mutants.
In summary these data show that APL-1 regulates late endosomal morphology in concert
with the PPK-3 complex.
Fig 4. APL-1 overexpression, while able to rescue partial loss of PPK-3 function, failed to rescue the ppk-3(mc46) null allele. (A) Expression of APL-
1::GFP failed to rescue lethality of ppk-3 null animals and failed to rescue vacuolation in apl-1::GFP; ppk-3(mc46) animals. Bar, 50μm. (B) Quantification of
the relative vacuolated area in ppk-3(mc46) and apl-1::GFP; ppk-3(mc46) animals showed that APL-1 overexpression failed to rescue complete loss of PPK-
3 function (n38, p = 0.73 (two-tailed t-test), suggesting that APL-1 functions upstream of PPK-3.
doi:10.1371/journal.pone.0130485.g004
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Fig 5. Mutations in apl-1 and ppk-3 or vacl-14 lead to defective processing of late endosomes and
lysosomes in young adults. (A) In control animals and single apl-1(yn5), vacl-14(ok1877) and ppk-3
(n2835) mutants late endosomes stained using GFP::RAB-7 as a marker were visible as vesicles or small
vacuoles. Combination of the mutations in apl-1(yn5); vacl-14(ok1877) or apl-1(yn-5) ppk-3(n2835) double
mutants led to a drastic alteration of the morphology of the late endosomal compartment, e.g. late
APP Controls PIKfyve Function
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APP and PIKfyve control neuronal functions
As defective PIKfyve function has been shown to cause profound neurodegeneration in mice
and in humans [21, 25] and as APP is crucially implicated in Alzheimer's disease we wanted to
test whether mutations in apl-1, ppk-3 or vacl-14 can lead to impaired neuronal function in C.
elegans. We characterised the overall morphology of the neuronal system of C. elegans using
the synaptic marker GFP::RAB-3 by fluorescence microscopy (Fig 6). In single apl-1(yn5) and
ppk-3(n2835)mutants the neuronal system appeared to be largely unaffected. However, the
apl-1(yn5) ppk-3(2835) double mutant failed to accumulate GFP::RAB-3 label in the character-
istic “pearls-on-a-string” fashion to the same extent compared to control animals, leading to
more homogeneous RAB-3 staining along the ventral nerve chord (Fig 6). Lack of concentrat-
ing RAB-3 vesicles in synapses along the ventral nerve chord suggests that synaptic transmis-
sion may be impaired.
We wanted to also assess whether the interplay of APL-1 and PPK-3 is functionally impor-
tant. For this we tested the ability of single and double mutants to coordinate motor function
using a thrashing assay. C. elegans reacts with rapid and sustained thrashing when placed in liq-
uid, a simple assay for testing synaptic transmission of the main motor neurotransmitters, glu-
tamate and gamma amino butyric acid (GABA). While the single mutants apl-1(yn5), vacl-14
(ok1877) and ppk-3(n2835) displayed no significant impairment of motor control, the apl-1
(yn5) ppk-3(n2835) and apl-1(yn5); vacl-14(ok1877) double mutants were both significantly
impaired in their ability to thrash (Fig 6). Together with the RAB-3 morphological data this
demonstrates that the APL-1/PPK-3 interplay is necessary for supporting neuronal function.
Discussion
To date the regulation of the PIKfyve complex has remained unclear in multicellular organ-
isms. Our genetic analysis of the interplay between the C. elegans orthologues of APP and the
PIKfyve complex suggests that APP controls the PIKfyve pathway in-vivo. This is evidence for
a completely novel and unexpected function of APP.
As a working model we would like to propose that APP, upon arrival to endosomes, inter-
acts with and activates the PIKfyve complex to stimulate processes such as endosome-to-TGN
transport and endosome/lysosome fusion (Fig 7). Previous work in multiple systems has estab-
lished that APP/APL-1 traffics through the endosomal system, which in C. elegans is required
for maintenance of APL-1 [35]. The system we describe here would link APP trafficking to the
production of the crucial endosomal signalling lipid PI(3,5)P2 and potentially PI(5)P [17].
One of the many gaps in our understanding of the PIKfyve/PI(3,5)P2 system is through
which effectors PI(3,5)P2 mediates its effects. In mammals one of the few established effectors
is the endo/lysosomal, Ca2+-selective TRPML1 channel, also known as mucolipin [18]. Dong
and colleagues demonstrated that drop of PI(3,5)P2 levels caused by PIKfyve deficiency pre-
vents activation of TRPML1, thus blocking Ca2+ release from the lumen of endosomes. This
release is required for endo/lysosomal fusion events. Impaired lysosomal fusion blocks the flux
endosomes became tubular and clustered in the hypoderm and intestine when comparing double with single
mutants. While in single mutants individual compartments were abundant, they appeared 'squashed' and
tubular in the double mutants (indicated by arrows). (B) Analysis of the lysosomal marker GFP::LMP-1
showed that in single apl-1(yn5), vacl-14(ok1877) and ppk-3(n2835) mutants distinct, LMP-1 positive
vacuoles of variable sizes were apparent. However, in apl-1(yn5); vacl-14(ok1877) and apl-1(yn5) ppk-3
(n2835) double mutants the LMP-1 positive structures appeared aggregated, mimicking the defect observed
in GFP::RAB-7 worms, suggesting a defect in late endosomal and lysosomal trafficking. These data showed
that APL-1 and the PPK-3 complex are required for late endosomal processing. Bar, 100μm.
doi:10.1371/journal.pone.0130485.g005
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through the endosomal system leading to endosomal swelling [18]. Interestingly, mutations in
mucolipin lead to lysosomal storage disease and neurodegeneration [19].
While it is clear that APP's processing is intimately linked with Alzheimer's disease there is
currently no clear mechanistic model for the molecular events that lead to the induction and
progression of this disease. For the last two decades the amyloid cascade hypothesis has domi-
nated the field. Its core assumption is that production of beta amyloid initiates a cascade that
ultimately leads to 'plaque' deposition in patients' brains, formation of neurofibrillar tangles
and neuronal death resulting in neurodegeneration [37]. However, immunological approaches
of targeting beta amyloid production or deposition have essentially failed to stop cognitive
decline and neurodegeneration [38]. This raises the possibility that progression of Alzheimer's
disease is driven by processes other than beta amyloid accumulation [39, 40]. It is conceivable
Fig 6. APL-1/PPK-3 interplay is required for neuronal function. (A) The C. elegans synaptic marker GFP::RAB-3 was used to visualise the central
nervous system of control animals, single and double mutants. While the nervous system was intact at the light microscopic level in control animals and
single mutants, in the apl-1(yn5) ppk-3(n2835) double mutant the accumulation of the synaptic vesicle marker GFP::RAB-3 was impaired leading to a more
homogeneous, less well-defined staining of the ventral nerve chord. Enlargement of the respective areas is shown in the second row of panels. Bar, 50 μm.
(B) Average intensity difference between GFP::RAB-3 maxima (corresponding to synapses) and GFP::RAB-3 minima (intersynaptic space) measured along
the C. elegans ventral nerve chord demonstrated the reduced ability of the apl-1(yn5) ppk-3(n2835) double mutant to concentrate RAB-3 in synapses
compared to the N2 control (p<0.01, two-tailed t-test, n>13). Error bars are s.e.m. (C) Thrashing analysis of single and double mutants demonstrated that the
interplay between APL-1 and the PPK-3 complex is required for motor control in C. elegans. The double mutants apl-1(yn5); vacl-14(ok1877) and apl-1
(yn5) ppk-3(n2835) were significantly impaired in their thrashing compared to the Bristol N2 and lon-2(e678) controls and the single mutants (p values
student’s t-test <0.01, n = 20 per strain). Error bars are s.e.m.
doi:10.1371/journal.pone.0130485.g006
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that loss-of-APP function rather than the toxic gain-of-function of beta amyloid drives neuro-
degeneration in Alzheimer's disease. However, as the cellular function of APP remained
unclear, describing how loss of APP function could contribute to Alzheimer’s disease was not
possible to date [41]. Our finding that APP regulates the PIKfyve complex in C. elegans in vivo
hints at a novel molecular mechanism for neurodegeneration in Alzheimer's disease in which
aberrant processing of APP by beta and gamma secretases would preclude APP from binding
to and activating the PIKfyve complex. This would lead to a drop of endosomal PI(3,5)P2 level
which would disrupt endosomal sorting and homeostasis through a lack of activation of PI
(3,5)P2 effectors, the TRPML1 channel mucolipin being one of them [18]. Loss of PIKfyve sub-
units and TRPML1 are well known to result in neurodegeneration. This idea would also
account for the aberrant accumulation of vesicles with endo- and lysosomal characteristics
observed in the brains of Alzheimer's patients (reviewed in [42]). Damage to the endo/
Fig 7. Workingmodel for the interplay of APP with the PIKfyve complex to control endosomal sorting and homeostasis. APP is well known to traffic
between the trans-Golgi-network (TGN), the plasmamembrane (PM) and the endosomal system consisting of early endosomes (EE), late endosomes (LE)
and lysosomes ([10] and references therein). The PIKfyve complex phosphorylates PI(3)P to PI(3,5)P2 (indicated by red labelling of the membrane) which is
crucial for endosome-to-TGN transport, endosomal homeostasis [15, 18, 25] and other endosomal sorting processes during the maturation of endosomes
[47]. In this study we have shown that APP can associate via its intracellular domain with Vac14 of the PIKfyve complex and that the C. elegans APP
orthologue APL-1 functionally cooperates with the PIKfyve/PPK-3 complex in C. elegans. We propose a working model in which APP/APL-1 traffics through
the vesicular transport system and, upon arrival in endosomes, interacts with the PIKfyve/PPK-3 complex via its intracellular domain. The genetic data
obtained in C. elegans suggest that APL-1 stimulates PPK-3 activity which is necessary to maintain endosomal function. Compromised PIKfyve/PPK-3
function impacts on endosomal sorting and homeostasis which in C. elegans as well as in mammals has detrimental consequences for neuronal function and
integrity [17, 25, 26].
doi:10.1371/journal.pone.0130485.g007
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lysosomal system of neuronal cells will impact on the clearance of beta amyloid by endocytosis
and lysosomal degradation, potentially explaining the accumulation of beta amyloid and the
resulting pathological effects of this molecule.
Exploring this idea will yield fascinating insights into the regulation and significance of the
PI(3,5)P2 metabolism and may redefine our view of Alzheimer’s disease.
Materials and Methods
Antibodies
The antibody directed against Vac14 was kindly provided by Prof. L. Weisman (University of
Michigan). Antibodies against EEA1 were purchased from BD Biosciences and Lampl from
Santa Cruz Biotechnology.
Proteo-liposomes
Protein recruitments and mass spectrometry were carried out as established in [27] with the
following modifications: 0.5ml of mouse brain cytosol (final concentration 3mg/ml) were used
supplemented with 0.21mM GTPγS and 28μM latrunculin B. The xcalibur.raw files were pro-
cessed with MaxQuant and the Perseus software of this package was used for analysis as
described in [30]. Briefly, LFQ intensities were logarithmised and only proteins that were iden-
tified in all replicates of at least one of the samples were retained. Missing values were imputed
by a normal distribution around the detection limit and a modified t-test (SAM) was per-
formed with a threshold value of 0.05 and a slope value of 1. A detailed description of the
method is presented in [43].
C. elegansmethods and strains
Worm maintenance, genetic crosses and other C. elegansmethods were performed according
to standard protocols [44]. All strains were grown at 20°C. Mutations used were LGI, vacl-14
(ok1877); LGX, apl-1(yn5) lon-2(e678), lon-2(e678), ppk-3(n2835), ppk-3(n2668)[33]. vacl-14
(ok1877) was back-crossed three times to WT strain N2 prior to further analysis. The ok1877
deletion was followed by PCR. As negative controls either Bristol N2 wildtype or lon-2(e678)
were used as the apl-1(yn5)mutation is in close proximity to the lon-2 locus which served as a
marker to follow the yn5 deletion throughout crosses.
Strains carrying integrated arrays used in this study were: pwIs50 (plmp-1::LMP-1::GFP),
pwIs439 (prab-5::GFP::RAB-5), pwIs399 [prab-7::GFP::RAB-7) were kindly provided by Prof.
B.Grant, jsIs682 [prab-3::GFP::RAB-3) by CGC. For RNA interference (RNAi) experiments,
apl-1 cDNA was prepared from EST clone provided by Prof. Kohara (National Institute of
Genetics, Japan) and subcloned into RNAi feeding vector L4440 [45]. RNA interference
(RNAi) was performed by the feeding method [45]. For RNAi knockdown of apl-1, L1 worms
were placed onto RNAi plates, and P0 adults were scored for phenotype after 72 h.
Transgenic strain
The transgenic APL-1::GFP strain was produced as previously described [46]. Briefly, N2 ani-
mals were bleached and synchronised. Young adults were picked with an eyelash and placed
on an injection pad (2% agarose in M9 buffer). Worms were coinjected with 50 ng/μl apl-1 fos-
mid (Construct: 10208337314574834 H09, obtained from TransgeneOme) and 120 ng/μl pRF4
roller plasmid as coinjection marker. 20–30 worms were injected and analysed for GFP positive
offspring. GFP positive offspring was isolated to create line OL0186.
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Vacuole number and size
was detected using ImageJ by manual circling each individual vacuole present in a DIC image
of the anterior tip of the worm and measuring number and size of them using the “Analyse
Particle” command.
GFP::RAB-3 accumulation
Using ImageJ the intensity profile of GFP::RAB-3 was established along the ventral nerve
chord using manually created line plots, maximas and minimas detected and the average inten-
sity difference between maxima and minima were calculated.
Thrashing assay
L4 larval stage animals were picked onto fresh OP50 seeded plates and scored for thrashing as
young adults 24 hours later. Individual animals were transferred into 30μl drop of M9 buffer
into a depression well slide and thrashing was scored for 1 minutes after worms were allowed
to settle for 1 minute. A single thrash was defined as a complete change in the direction of the
body down the midline.
Microscopy
Fluorescence and DIC images were obtained using a fully motorized Zeiss Axiovert 200M fluo-
rescence microscope (Carl Zeiss) and a Hamamatsu Orca camera controlled by Volocity soft-
ware (Improvision). Confocal images were obtained using a Leica SP5 upright confocal
microscopy setup. To observe live worms expressing transgenes, worms were mounted on 2%
agarose pads containing 0.1M tetramisole in M9 buffer.
Vesicle tracking
was performed using the 'Manual Tracking' plugin in ImageJ.
Intensity quantification of RAB-3 staining
Quantification was performed using ImageJ. Briefly, a line was manually drawn along the ven-
tral nerve chords and the pixel intensity were measured in a line plot. Intensity maxima and
minima were defined and the average difference between the two was measured.
Supporting Information
S1 Fig. Line scans in HeLa cells expressing APP-CFP and Vac14-mCIT highlight colocalisa-
tion between APP and Vac14.
(TIF)
S2 Fig. Truncation of APL-1 in ppk-3 or vacl-14mutants significantly enhanced the vacuo-
lar phenotype.DIC images were collected from the vulval area of young control adults (Bristol
N2), single and double mutants. Examples of vacuoles are labelled with arrows, asterisks indi-
cate very large vacuoles. The apl-1(yn5) ppk-3(n2835) and apl-1(yn5); vacl-14(ok1877) dis-
played significantly larger and more vacuoles than the single mutants or wildtype controls.
Note that the apl-1(yn5) ppk-3(n2668) were heavily vacuolated and did not produce viable off-
spring. Bar, 50μm.
(TIF)
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S3 Fig. RNAi suppression of APL-1 in control animals and ppk-3mutants enhances the
vacuolar phenotype caused by loss of PPK-3 activity. The mutants indicated in the left col-
umn were fed with a bacterial strain containing a control RNAi-plasmid (L4440), in the right
column a strain containing an APL-1 targeting RNAi plasmid. Arrows indicate vacuoles in
hypodermal cells. Asterisks indicate very large vacuoles.
(TIF)
S4 Fig. Characterisation of early endosomes in APL-1 and PPK-3 mutants. The early endo-
somal, RAB-5 positive compartment remained largely unaffected by mutations in apl-1 and
the PPK-3 complex. Bar, 100μm.
(TIF)
S5 Fig. RNAi suppression of APL-1 in animals with impaired PPK-3 function enhanced
late endosomal defects as visualised by GFP::RAB-7. Suppression of APL-1 (right column)
altered the morphology of late endosomes with mutations in ppk-3 and vacl-14 compared with
the control RNAi L4440 (left). Late endosomes appeared to either aggregate, swell in size (indi-
cated by arrows) or undergo tubulation with the effects most visible in hypodermal cells. Bar,
50μm.
(TIF)
S6 Fig. APL-1 expression pattern of N2 transfected with a fosmid encoding a genomic copy
of APL-1 tagged with GFP. APL-1::GFP expression is detected in neuronal and non-neuronal
cells, amongst them head muscle cells (A), the nerve chord (indicated by arrow) (B), the hypo-
derm (C) and the intestine (D). DIC images are indicated by'. Bar, 50μm.
(JPG)
S1 Video. Colocalisation and comigration of vesicles labelled with APP-mCherry (red) and
Vac14-mCit (green) in transiently transfected HeLa cells. Speed ~8x.
(AVI)
S2 Video. Colocalisation and comigration of vesicles labelled with AICD-mCherry (red)
and Vac14-mCit (green) in transiently transfected HeLa cells. Speed ~8x.
(AVI)
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